Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2023-08-16 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司2023年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a '2023 半年度报告摘要' which translates to '2023 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including assets, net profit, earnings per share, and shareholder information. The document length is 8184 characters, which is substantial and contains actual financial data and analysis. It explicitly states it is a half-year report summary derived from the full half-year report. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains substantive financial data and analysis. There is no indication that this is merely an announcement or a certification, and it is not a full annual report. Therefore, the correct classification is IR. H1 2023
2023-08-16 Chinese
西部证券股份有限公司关于圣湘生物科技股份有限公司2023半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2023年半年度持续督导跟踪报告" which translates to "2023 Semi-Annual Continuous Supervision Follow-up Report." It is issued by a sponsor (保荐人) responsible for continuous supervision of a listed company, 圣湘生物科技股份有限公司. The document contains detailed financial data for the half-year period ending June 30, 2023, including revenue, net profit, cash flow, and other financial indicators. It also discusses risks, core competitiveness, R&D progress, and compliance with regulatory requirements. The document is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement or a certification, but a full report with detailed financial and operational information for the half-year period. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2023
2023-08-16 Chinese
圣湘生物科技股份有限公司关于使用部分暂时闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 圣湘生物科技股份有限公司 regarding the use of temporarily idle raised funds for cash management. It details the board meeting resolutions, investment purpose, scope, risk control measures, and opinions from independent directors, the supervisory board, and the sponsor. The document does not contain financial statements or detailed financial data but is a formal disclosure about the company's financing fund usage and related approvals. It is not an annual or interim report, audit report, or earnings release. It is a regulatory announcement about capital usage and compliance with securities regulations. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3283 characters, which is typical for an announcement rather than a full report.
2023-08-16 Chinese
圣湘生物科技股份有限公司独立董事关于第二届董事会2023年第九次临时会议相关事宜的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at a specific board meeting, including a report on the use of raised funds and a proposal for cash management of idle raised funds. It references compliance with regulatory rules and internal company policies. The content is focused on board-level decisions and independent directors' assessments rather than full financial statements or earnings data. The document length is short (801 characters) and it is not a full report but an opinion related to board matters. Therefore, it fits best under Board/Management Information (MANG).
2023-08-16 Chinese
圣湘生物科技股份有限公司持股5%以上股东集中竞价减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a major shareholder's plan to reduce their shareholding through centralized bidding transactions. It details the shareholder's current holdings, previous reduction activities, the planned reduction amount, timing, and compliance with relevant securities laws and stock exchange regulations. The document does not contain financial statements, earnings data, or management discussion but focuses on shareholding changes by a significant shareholder. This fits the definition of a Major Shareholding Notification (MRQ), which involves notifications of changes in significant share ownership levels.
2023-08-09 Chinese
圣湘生物科技股份有限公司关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 圣湘生物科技股份有限公司 regarding the progress of its share repurchase program through centralized bidding transactions. It details the board's approval of the buyback plan, the price limits, the total amount authorized, and the progress of shares repurchased up to July 31, 2023. The document does not contain financial statements or detailed financial analysis but focuses on the update of the company's own share transactions. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2023-08-01 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.